Oncocyte Corporation (OCX) announced that it has appointed leading finance executive, Andrea James, to the position of Chief Financial Officer. “We are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy through multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team. Prior to joining Oncocyte, Ms. James served as Chief Communications Officer and head of investor relations at Axon Enterprise (AXON). Ms. James worked in a strategic investor relations role for Tesla (TSLA) in 2016 and 2017. From 2009 to 2016 she worked as a sell-side analyst for Dougherty & Company becoming a vice president and senior research analyst. At Dougherty, she researched emerging technologies on behalf of institutional investors. Previously, she was a reporter at publications including Bloomberg News and the Seattle Post-Intelligencer covering a range of business and financial beats.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCX:
- OncoCyte Executive Team Receives Significant Salary Increases
- OncoCyte announces VitaGraft Kidney data published in NEJM
- Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
- OncoCyte reports Q1 EPS ($1.13), consensus (67c)
- OncoCyte files to sell 5.42M shares of common stock for holders